跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

SML1391

Sigma-Aldrich

Olmesartan medoxomil

≥98% (HPLC)

别名:

4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, CS-866

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C29H30N6O6
CAS号:
144689-63-4
分子量:
558.59
MDL编号:
MFCD00944911
UNSPSC代码:
12352200
PubChem化学物质编号:
329825839
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 10 mg/mL, clear

储存温度

2-8°C

SMILES字符串

CCCC1=NC(C(O)(C)C)=C(C(OCC2=C(C)OC(O2)=O)=O)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5

InChI

1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)

InChI key

UQGKUQLKSCSZGY-UHFFFAOYSA-N

基因信息

human ... AGTR1(185)

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Olmesartan medoxomil is a selective Angiotensin II Type I receptor blocker and antihypertensive drug. Olmesartan medoxomil is converted enzymatically to the active form olmesartan.
Olmesartan medoxomil is considered as an antihypertensive agent. It is an angiotensin 2 type 1 antagonist receptor. It is a prodrug which releases the parent compound olmesartan after ingestion. Olmesartan is ejected via kidney and liver. In humans, olmesartan protects renal and cardiovascular systems. This drug may be used in the treatment of hypertension.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H302 + H312 + H332

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000395009
0000390476
0000390476
0000307575
0000307575

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Angiotensin II Inhibitors: Advances in Research and Application (2012)
Current Cardiovascular Drugs (2005)
Hans R Brunner
Journal of human hypertension, 16 Suppl 2, S13-S16 (2002-04-23)
The new orally active angiotensin II (A II) type-1 receptor antagonist olmesartan medoxomil is a prodrug, which is rapidly converted in vivo to the active metabolite, olmesartan. The pharmacology, antihypertensive efficacy and safety of olmesartan medoxomil and/or the pharmacologically active
Case Studies in Modern Drug Discovery and Development (2012)
Linear mixed-effects model of QTc prolongation for olmesartan medoxomil.
SaeHeum Song et al.
Journal of clinical pharmacology, 56(1), 96-100 (2015-06-23)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门